Related Experiment Video
Updated: May 25, 2026
Brain Source Imaging in Preclinical Rat Models of Focal Epilepsy using High-Resolution EEG Recordings
Published on: June 6, 2015
Identification of new epilepsy treatments: issues in preclinical methodology
Aristea S Galanopoulou1, Paul S Buckmaster, Kevin J Staley
1Laboratory of Developmental Epilepsy, Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine, Bronx, NY, USA. aristea.galanopoulou@einstein.yu.edu
Abstract:
Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.
Insights
New preclinical research guidelines are needed for epilepsy treatments. This framework aims to improve drug development for drug-resistant seizures, epileptogenesis, and comorbidities, addressing unmet clinical needs.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Research
Background:
- Epilepsy treatment remains challenging, with a third of patients experiencing uncontrolled seizures despite existing therapies.
- Comorbidities associated with epilepsy significantly impact patients' quality of life.
- Current antiseizure medications have limited efficacy for a substantial patient population.
Purpose of the Study:
- To establish a framework for preclinical antiepilepsy therapy development.
- To guide the design, reporting, and validation of studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.
- To address unmet clinical needs in epilepsy treatment, including age- and gender-specific therapies.
Main Methods:
- Review of preclinical research in epilepsy therapy development.
- Identification of key areas for improvement in study design and validation.
- Development of standardized guidelines for future research.
Main Results:
- Current preclinical development for epilepsy therapies is complex and requires standardization.
- A need exists for novel symptomatic and disease-modifying treatments.
- Guidelines are proposed to improve the preclinical evaluation of antiepilepsy drugs.
Conclusions:
- Standardized preclinical research guidelines are crucial for advancing epilepsy treatment.
- The proposed framework will aid in developing more effective therapies for drug-resistant epilepsy, epileptogenesis, and comorbidities.
- Future research should focus on tailored treatments for diverse patient subpopulations.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:28Preclinical Development: Overview